MDN1 and neoplasm: Moreover, a mutation in Mitochondrial Dysfunctional 1 (MDN1) was enriched in drug metabolism cytochrome P450 pathways and associated with a high tumor mutational burden (TMB) and poorer prognosis in patients with BRCA.